Pre-operative screening and post-operative monitoring in adult patients with obstructive sleep apnea: clinical effectiveness and guidelines
Canadian Agency for Drugs and Technologies in Health
Record ID 32011001187
English
Authors' recommendations:
PSG is the gold standard to evaluate patients with suspected OSA in the current practice; however, its use is restricted due to the time commitment, resource availability, and complex results interpretation. Evidence of the performance of several validated screening tools was identified. The studies suggested that all tools showed acceptable diagnostic accuracy in screening pre-surgical patients with suspected OSA, and the 4-item STOP questionnaire is a shorter questionnaire so may be easier to use compared to the others (10-item Berlin questionnaire and 16-item ASA checklist). According to two clinical practice guidelines, oximetry can be used in patient monitoring after surgery. Opioid analgesics are not recommended to be prescribed to postoperative patients with OSA; non-opioid analgesics such as nonsteroidal anti-inflammatory analgesics are an option for postoperative pain management. One guideline stated that patients with OSA may require a longer hospital or critical care unit stay compared with those undergoing similar procedures but without OSA.It remains unclear whether the perioperative risks could be reduced by appropriate screening to detect undiagnosed OSA and implementation of a perioperative management plan for patients with OSA. Further well-designed clinical studies would provide more rigorous evidence to fill the gap.
Details
Project Status:
Completed
Year Published:
2010
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Postoperative Care
- Preoperative Care
- Sleep Apnea, Obstructive
- Treatment Outcome
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.